Source-grounded facts extracted from Inhibitor Therapeutics, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Inhibitor Therapeutics, Inc. entered into Securities Purchase Agreement with an institutional investor valued at $3,000,000 (effective 2026-02-19).
“On February 19, 2026, Inhibitor Therapeutics, Inc. (the “ Company ”) entered into a Securities Purchase Agreement (the “ SPA ”) with an institutional investor (the “ Investor ”), for certain financing (the “Financing”), pursuant to which the Company has agreed to sell to the Investor 12,000,000 shares of its common stock, par value $0.0001 per share (the “Common Stock”) and to issue to the Investor a Common Stock Purchase Warrant to purchase up to 7,000,000 shares of Common Stock (the “Warrant”), in consideration for the Investor’s investment of $3,000,000 therefor ($0.25 per share of Common Stock and accompanying Warrant).”
Material Agreements
Inhibitor Therapeutics, Inc. entered into Exclusive License Agreement with Johns Hopkins University valued at License agreement including upfront license fee, minimum annual royalty payments, royalties on net s (effective 2023-12-12).
“On December 12, 2023, Inhibitor Therapeutics, Inc. (the “Company”) entered into an Exclusive License Agreement (the “Agreement”) with Johns Hopkins University (“JHU”).”
Michelle Yanez was appointed as Director at Inhibitor Therapeutics, Inc..
“On October 13, 2023, the Board of Directors (the “ Board ”) of Inhibitor Therapeutics, Inc. (the “ Company ”) appointed Michelle Yanez to fill one of the vacancies of the Board.”
Governance Changes
Inhibitor Therapeutics, Inc.: The Board amended the Bylaws to increase the stockholder vote threshold for bringing business at annual meetings, expand CFO and Secretary roles, provide indemnification reimbursement, raise the amendment/repeal/removal vote threshold to 66 2/3%, and remove references to the Equity Holders Agreement (effective 2023-07-12).
“On July 12, 2023, the Board amended the Bylaws (the “ Amended and Restated Bylaws ”) to, among other things: (i) provide that stockholders holding an aggregate of at least 50% of the entire capital stock issued and outstanding and entitled to vote at the meeting are required in order to bring business to be conducted at an annual meeting; (ii) expand the roles and duties of a Chief Financial Officer and a Secretary of the Company; (iii) to provide for the reimbursement of indemnified individuals in accordance with the laws of Delaware; (iv) increased the threshold of stockholder votes required for the amendment, repeal, or removal of the Amended and Restated Bylaws from a majority of the stockholders entitled to vote at such meeting to sixty-six and two-thirds percent (66 2/3%) of the stockholders entitled to vote at such meeting, and (v) remove all references and requirements related to the Amended and Restated Equity Holders Agreement by and among the Corporation, Mayne Pharma Ventur”
Ronald E. Osman was appointed as Director at Inhibitor Therapeutics, Inc..
“On August 23, 2023, the Board of Directors (the “ Board ”) of Inhibitor Therapeutics, Inc. (the “ Company ”) increased the number of directors on the Board from four (4) members to seven (7) members and appointed Ronald E. Osman to fill one of the vacancies of the Board.”
Michael Jerman was appointed as Director at Inhibitor Therapeutics, Inc..
“On May 24, 2023, the Board of the Company appointed Michael Jerman, CPA. as an independent member of its Board.”
Michelle Yanez resigned as Director at Inhibitor Therapeutics, Inc..
“On and effective May 24, 2023, Michelle Yanez gave notice to Inhibitor Therapeutics, Inc. (the “Company”) of her resignation from the Board of Directors of the Company (the “Board”).”
M&A Transactions
Inhibitor Therapeutics, Inc. underwent a change of control involving Mayne Pharma Ventures Pty Ltd. (closed 2022-12-13).
“the Board of the Company has concluded that a change of control of the Company occurred on December 13, 2022.”
Material Agreements
Inhibitor Therapeutics, Inc. terminated Third Amended and Restated Supply and License Agreement with Mayne Pharma Ventures Pty Ltd..
“Due to the events described in Items 1.01 of this Current Report on Form 8-K, the Company and Mayne Pharma terminated the Third Amended and Restated Supply and License Agreement.”
Material Agreements
Inhibitor Therapeutics, Inc. entered into License Agreement with Mayne Pharma Ventures Pty Ltd. (effective 2022-12-13).
“Additionally, on the Effective Date, the Company and Mayne entered into a license agreement (the “License Agreement”) pursuant to which the Company grants Mayne a worldwide, royalty-free, nonexclusive, perpetual, irrevocable license to certain of the Company’s Patents (as defined in the License Agreement) to the extent they relate to or have potential application in connection with the Product (as defined in the License Agreement).”
Material Agreements
Inhibitor Therapeutics, Inc. entered into Stipulation and Agreement of Compromise, Settlement, and Release with Mayne Pharma Ventures Pty Ltd., Hedgepath LLC, Samuel P. Sears, and the Individual Defendants valued at $14,250,000 in cash (effective 2022-09-09).
“On September 9, 2022, HPLLC, Sears, the Company, the Individual Defendants and Mayne Pharma entered into a Stipulation and Agreement of Compromise, Settlement, and Release, dated and filed with the Court (together with the exhibits thereto, the “Settlement Agreement”), which the Court approved, and the Settlement Agreement went into effect on December 13, 2022 (the “Effective Date”).”
Francis E. O'Donnell, Jr. was appointed as Chief Executive Officer at Inhibitor Therapeutics, Inc..
“On December 13, 2022, the Board of the Company appointed Francis E. O’Donnell, Jr., M.D. as Executive Chairman of its Board and as Chief Executive Officer of the Company.”
Francis E. O'Donnell, Jr. was appointed as Executive Chairman at Inhibitor Therapeutics, Inc..
“On December 13, 2022, the Board of the Company appointed Francis E. O’Donnell, Jr., M.D. as Executive Chairman of its Board and as Chief Executive Officer of the Company.”
Garrison J. Hasara resigned as other_named_officer at Inhibitor Therapeutics, Inc..
“On December 10, 2022, and in furtherance of the transactions contemplated by the Settlement Agreement, Nicholas J. Virca and Garrison J. Hasara (collectively, the “Resigning Officers”) gave notice of the Company of their resignation from their officer positions to be effective on December 13, 2022.”
Nicholas J. Virca resigned as other_named_officer at Inhibitor Therapeutics, Inc..
“On December 10, 2022, and in furtherance of the transactions contemplated by the Settlement Agreement, Nicholas J. Virca and Garrison J. Hasara (collectively, the “Resigning Officers”) gave notice of the Company of their resignation from their officer positions to be effective on December 13, 2022.”
Robert D. Martin resigned as Director at Inhibitor Therapeutics, Inc..
“On December 10, 2022, and in furtherance of the transactions contemplated by the Settlement Agreement, W. Mark Watson, Stefan J. Cross, Dr. R. Dana Ono, and Robert D. Martin (collectively, the “Resigning Directors”) gave notice of the Company of their resignation from the Board to be effective on December 13, 2022.”
Dr. R. Dana Ono resigned as Director at Inhibitor Therapeutics, Inc..
“On December 10, 2022, and in furtherance of the transactions contemplated by the Settlement Agreement, W. Mark Watson, Stefan J. Cross, Dr. R. Dana Ono, and Robert D. Martin (collectively, the “Resigning Directors”) gave notice of the Company of their resignation from the Board to be effective on December 13, 2022.”
Stefan J. Cross resigned as Director at Inhibitor Therapeutics, Inc..
“On December 10, 2022, and in furtherance of the transactions contemplated by the Settlement Agreement, W. Mark Watson, Stefan J. Cross, Dr. R. Dana Ono, and Robert D. Martin (collectively, the “Resigning Directors”) gave notice of the Company of their resignation from the Board to be effective on December 13, 2022.”
W. Mark Watson resigned as Director at Inhibitor Therapeutics, Inc..
“On December 10, 2022, and in furtherance of the transactions contemplated by the Settlement Agreement, W. Mark Watson, Stefan J. Cross, Dr. R. Dana Ono, and Robert D. Martin (collectively, the “Resigning Directors”) gave notice of the Company of their resignation from the Board to be effective on December 13, 2022.”
Debra Peattie retired as Director at Inhibitor Therapeutics, Inc..
“On and effective June 1, 2022, Debra Peattie, PhD, MBA gave notice to Inhibitor Therapeutics, Inc. (the “Company”) of her retirement from the Board of Directors of the Company (the “Board”).”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.